BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Preller KH, Vollenweider FX. Modulation of Social Cognition via Hallucinogens and "Entactogens". Front Psychiatry 2019;10:881. [PMID: 31849730 DOI: 10.3389/fpsyt.2019.00881] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Kiraga MK, Kuypers KPC, Uthaug MV, Ramaekers JG, Mason NL. Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. Front Psychiatry 2022;13:883869. [DOI: 10.3389/fpsyt.2022.883869] [Reference Citation Analysis]
2 Hayes C, Wahba M, Watson S. Will psilocybin lose its magic in the clinical setting? Ther Adv Psychopharmacol 2022;12:20451253221090822. [PMID: 35480296 DOI: 10.1177/20451253221090822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bălăet̨ M. Psychedelic Cognition—The Unreached Frontier of Psychedelic Science. Front Neurosci 2022;16:832375. [DOI: 10.3389/fnins.2022.832375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vollenweider FX, Smallridge JW. Classic Psychedelic Drugs: Update on Biological Mechanisms. Pharmacopsychiatry. [DOI: 10.1055/a-1721-2914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
5 Rodríguez Arce JM, Winkelman MJ. Psychedelics, Sociality, and Human Evolution. Front Psychol 2021;12:729425. [PMID: 34659037 DOI: 10.3389/fpsyg.2021.729425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Castelhano J, Lima G, Teixeira M, Soares C, Pais M, Castelo-Branco M. The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies. Front Pharmacol 2021;12:739053. [PMID: 34658876 DOI: 10.3389/fphar.2021.739053] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Langlitz N, Dyck E, Scheidegger M, Repantis D. Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics. Front Psychiatry 2021;12:680064. [PMID: 34408677 DOI: 10.3389/fpsyt.2021.680064] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Rocha JM, Rossi GN, de Lima Osório F, Bouso JC, de Oliveira Silveira G, Yonamine M, Campos AC, Bertozi G, Cecílio Hallak JE, Dos Santos RG. Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial. J Clin Psychopharmacol 2021;41:267-74. [PMID: 33843820 DOI: 10.1097/JCP.0000000000001396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Payne JE, Chambers R, Liknaitzky P. Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice. ACS Pharmacol Transl Sci 2021;4:416-23. [PMID: 33860171 DOI: 10.1021/acsptsci.1c00034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mertens LJ, Preller KH. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders. Pharmacopsychiatry 2021;54:176-90. [PMID: 33472250 DOI: 10.1055/a-1341-1907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
11 Cocchi V, Gasperini S, Hrelia P, Tirri M, Marti M, Lenzi M. Novel Psychoactive Phenethylamines: Impact on Genetic Material. Int J Mol Sci 2020;21:E9616. [PMID: 33348640 DOI: 10.3390/ijms21249616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 2020;27:100538. [PMID: 33150319 DOI: 10.1016/j.eclinm.2020.100538] [Cited by in Crossref: 17] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
13 Hidalgo S, Castro C, Zárate RV, Valderrama BP, Hodge JJL, Campusano JM. The behavioral and neurochemical characterization of a Drosophila dysbindin mutant supports the contribution of serotonin to schizophrenia negative symptoms. Neurochem Int 2020;138:104753. [PMID: 32416114 DOI: 10.1016/j.neuint.2020.104753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]